- Home
- CANF vs PYPD Comparison
CANF vs PYPD Comparison
Compare CANF & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PYPD
- Stock Information
- Founded
- CANF 1994
- PYPD 2008
- Country
- CANF Israel
- PYPD Israel
- Employees
- CANF N/A
- PYPD N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- CANF Health Care
- PYPD Health Care
- Exchange
- CANF Nasdaq
- PYPD Nasdaq
- Market Cap
- CANF 14.4M
- PYPD 16.3M
- IPO Year
- CANF N/A
- PYPD 2020
- Fundamental
- Price
- CANF $1.97
- PYPD $3.59
- Analyst Decision
- CANF Strong Buy
- PYPD Buy
- Analyst Count
- CANF 2
- PYPD 2
- Target Price
- CANF $14.00
- PYPD $12.00
- AVG Volume (30 Days)
- CANF 116.8K
- PYPD 4.6K
- Earning Date
- CANF 11-15-2024
- PYPD 11-06-2024
- Dividend Yield
- CANF N/A
- PYPD N/A
- EPS Growth
- CANF N/A
- PYPD N/A
- EPS
- CANF N/A
- PYPD N/A
- Revenue
- CANF $667,000.00
- PYPD N/A
- Revenue This Year
- CANF $356.93
- PYPD N/A
- Revenue Next Year
- CANF N/A
- PYPD N/A
- P/E Ratio
- CANF N/A
- PYPD N/A
- Revenue Growth
- CANF N/A
- PYPD N/A
- 52 Week Low
- CANF $1.81
- PYPD $2.95
- 52 Week High
- CANF $4.69
- PYPD $9.20
- Technical
- Relative Strength Index (RSI)
- CANF 35.55
- PYPD 52.68
- Support Level
- CANF $1.87
- PYPD $3.31
- Resistance Level
- CANF $2.04
- PYPD $3.75
- Average True Range (ATR)
- CANF 0.15
- PYPD 0.20
- MACD
- CANF 0.00
- PYPD 0.01
- Stochastic Oscillator
- CANF 18.18
- PYPD 61.25
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.